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Abstract
Background: Primary care providers’ suboptimal recognition of the severity of chronic kidney disease (CKD) may
contribute to untimely referrals of patients with CKD to subspecialty care. It is unknown whether U.S. primary care
physicians’ use of estimated glomerular filtration rate (eGFR) rather than serum creatinine to estimate CKD severity
could improve the timeliness of their subspecialty referral decisions.
Methods: We conducted a cross-sectional study of 154 United States primary care physicians to assess the effect
of use of eGFR (versus creatinine) on the timing of their subspecialty referrals. Primary care physicians completed a
questionnaire featuring questions regarding a hypothetical White or African American patient with progressing
CKD. We asked primary care physicians to identify the serum creatinine and eGFR levels at which they would
recommend patients like the hypothetical patient be referred for subspecialty evaluation. We assessed significant
improvement in the timing [from eGFR < 30 to ≥ 30 mL/min/1.73m
2) of their recommended referrals based on
their use of creatinine versus eGFR.
Results: Primary care physicians recommended subspecialty referrals later (CKD more advanced) when using
creatinine versus eGFR to assess kidney function [median eGFR 32 versus 55 mL/min/1.73m
2, p < 0.001]. Forty
percent of primary care physicians significantly improved the timing of their referrals when basing their
recommendations on eGFR. Improved timing occurred more frequently among primary care physicians practicing
in academic (versus non-academic) practices or presented with White (versus African American) hypothetical
patients [adjusted percentage(95% CI): 70% (45-87) versus 37% (reference) and 57% (39-73) versus 25% (reference),
respectively, both p ≤ 0.01).
Conclusions: Primary care physicians recommended subspecialty referrals earlier when using eGFR (versus
creatinine) to assess kidney function. Enhanced use of eGFR by primary care physicians’ could lead to more timely
subspecialty care and improved clinical outcomes for patients with CKD.
Background
Chronic kidney disease (CKD) is a growing public health
problem with over ten percent of United States (U.S.)
adults having some form of kidney damage and/or
decreased kidney function[1]. Patients with CKD are at
increased risk of poor clinical outcomes including cardi-
ovascular disease, hospitalizations, and death[2]. Timely
referral of patients with CKD to specialist care has been
shown to improve the morbidity and mortality
associated with CKD[3,4]. Therefore, clinical practice
guidelines recommend patients with CKD receive sub-
specialty referrals when their glomerular filtration rate is
less than 30 mL/min/1.73m
2 to provide adequate time
to manage the late complications of CKD and to pre-
pare patients for renal replacement therapy[5-8]. Guide-
lines further advise referrals occur earlier (glomerular
filtration rate greater than 30 mL/min/1.73m
2)w h e n
patients show evidence of risk factors for rapid CKD
progression, to exclude primary renal diseases when the
etiology of CKD is unclear, and for the management of
the early sequelae (including anemia and bone disease)
of CKD, which are associated with poor clinical
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care physicians, who care for a majority of the growing
number of patients with stage 3 CKD, have been shown
in multiple studies to have difficulties recognizing the
severity of CKD, which may contribute to missed or late
referrals[9-19].
Some primary care physicians’ suboptimal recognition
of the severity of CKD may be due, in part, to their use
of serum creatinine to estimate kidney function, which
is considerably less precise than more recently devel-
oped equation-based estimates of the glomerular filtra-
tion rate (eGFR)[20,21]. Studies suggest U.S. primary
care physicians’ use of eGFR has been widely variable
[10,13,16-19]. Since its inception in 2002, the National
Institutes of Health’s National Kidney Disease Education
Program (NKDEP) has encouraged clinical laboratories
to automatically report eGFR along with patient labora-
tory results whenever a serum creatinine is ordered to
facilitate the use of eGFR in clinical decision making for
patients with CKD[22]. Although a majority of larger
laboratories in the U.S. currently report eGFR (77%),
less than half (38%) of all clinical laboratories nation-
wide calculate and report eGFR[22-24].
It is unknown whether the timing of U.S. primary care
physicians’ decisions to refer their patients with CKD to
subspecialty care could be improved by their use of
eGFR rather than serum creatinine to estimate CKD
severity. Evidence of an effect of the use of eGFR on U.
S. primary care physicians’ CKD management decisions
could influence the expansion of efforts to educate pri-
mary care providers regarding the use of eGFR to esti-
mate CKD severity and to encourage clinical
laboratories to automatically report eGFR to improve
the care of patients with CKD. In a national study, we
assessed the effect of U.S. primary care physicians’ use
of eGFR on the timing of their subspecialty referral
decisions for patients with CKD.
Methods
Identification of Study Participants
As part of a national cross-sectional study conducted
between August 2004 and August 2005 to assess U.S.
physicians’ clinical care of patients with CKD, we
assessed whether primary care physicians’ use of eGFR
would affect the timing of their decisions to refer patients
to CKD subspecialty care. We identified a random strati-
fied sample of 400 family physicians, 400 internists, and
400 nephrologists using the American Medical Associa-
tion Physician Master File and mailed physicians a self-
administered questionnaire, which could be completed
on paper or using the Internet. Physicians were ineligible
for the study if they were not in active clinical practice or
were not contactable through the 7 total mailings and 4
reminder telephone calls. Participating physicians were
reimbursed $20. The Johns Hopkins Medicine Institu-
tional Review Board approved the study protocol.
We asked physicians several questions regarding their
preferred management of patients with progressing
advanced CKD, including two questions to assess the
threshold of kidney function at which they would refer
patients for subspecialty care based on their use of
either serum creatinine or eGFR to estimate kidney
function. Of the 959 physicians in active clinical prac-
tice, a total of 126 nephrologists and 178 primary care
physicians responded to the questionnaire. The intent of
this analysis was to assess the effect of eGFR reporting
on the timing of primary care physicians’ recommenda-
tions for subspecialty referral. We therefore limited our
study sample to the family physicians (n = 70) and
internists (n = 84) who answered both referral threshold
questions.
Questionnaire Content
We provided primary care physicians with one of four
randomly assigned hypothetical case scenarios featuring a
50 year-old female patient with hypertension and obesity
being evaluated by a primary care physician for the first
time. The hypothetical patient had advanced progressing
CKD, which would warrant subspecialty referral based on
U.S. and international subspecialty organization recom-
mendations[5-8]. Case scenarios varied randomly on
patient race (African American or White) and the pre-
sence or absence of diabetes. (Figure 1) The scenarios
revealed only the serum creatinine levels of the hypothe-
tical patient, as subsequent questions assessed physicians’
abilities to estimate eGFR from information provided in
the scenario[9]. Hypothetical patients’ serum creatinines
varied according to patient race to ensure all hypothetical
patients’ eGFRs (upon which clinical practice guidelines
for referral are based) would be similar.
To assess the effect of primary care physicians’ use of
eGFR on the timing of their subspecialty referral deci-
sions, we presented them with two visual analog scales,
one featuring a range of numbers reflecting kidney func-
tion measured using serum creatinine [ranging from
“<1.0 mg/dL” (better function) to “>6.0 mg/dL” (worse
function)] and one featuring numbers reflecting kidney
function measured using eGFR [ranging from 120 mL/
min/1.73m
2 (better function) to 0 mL/min/1.73m
2
(worse function)]. We asked physicians to mark on the
visual analog scales the serum creatinine level and the
eGFR level at which they would recommend a primary
care physician refer a patient, like the patient featured in
the hypothetical scenario, for subspecialty care. (Figure 2)
Assessment of Physician Characteristics
We assessed primary care physicians’ demographic and
practice characteristics [specialty (internists or family
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time performing clinical duties, number of years in prac-
tice, ZIP code of practice, and participation in educa-
tional resources (attend conferences, read scientific
journals, or other continuing medical education
activities]. We also asked primary care physicians to
select from a list the organizations they turn to for clini-
cal practice guidelines as well as their awareness and
compliance with guidelines regarding the referral of
patients with CKD. We dichotomized the number of
years in practice (≤ 10 years versus > 10 years) to reflect
the approximate time interval in which physicians are
required to enhance their clinical judgment and skills
through the clinical practice board re-certification pro-
cess[25,26]. Since most participating physicians spent
the majority of their time performing clinical duties, we
dichotomized their percent time performing clinical
duties at the 25
th percentile (<80% versus ≥ 80%).
Assessment of Timing of Primary Care Physicians’
Subspecialty Care Referrals
We assessed differences in the timing of primary care
physicians’ subspecialty referrals based on their use of
serum creatinine or eGFR by converting their selected
serum creatinine values to eGFR using the Modification
of Diet in Renal Disease Study equation[20]. We
accounted for the randomly assigned race of hypotheti-
cal patients in the calculation of the creatinine-based
eGFR. For each primary care physician, we calculated
the absolute difference (in mL/min/1.73m
2) between the
eGFR and creatinine-based eGFR levels at which physi-
cians recommended referral. The patient featured in the
hypothetical scenario was at increased risk of rapid CKD
progression and would therefore qualify for subspecialty
referral before the eGFR reached 30 mL/min/1.73m
2 or
less. We therefore considered primary care physicians’
recommendations for subspecialty referral to have clini-
cally significantly improved with their use of eGFR if
their serum creatinine-based referral recommendations
corresponded to an eGFR level of < 30 mL/min/1.73m
2,
but they recommended subspecialty referral at a level ≥
30 mL/min/1.73m
2 when using eGFR.
Statistical Analysis
We used bivariate (chi square, Wilcoxon rank-sum) ana-
lysis to assess differences in responding and non-
responding physicians’ number of years in practice and
census region. We used Wilcoxon rank sum test to
assess differences between the level of kidney function
at which primary care physicians’ recommended subspe-
cialty referrals based on serum creatinine versus eGFR.
We described the timing of primary care physicians’
referrals (eGFR < 30 versus ≥ 30 mL/min/1.73m
2)a n d
the proportion of primary care physicians with clinically
significant improvements in the timing of their referrals
when using eGFR versus serum creatinine to estimate
kidney function. We used multivariable logistic regres-
sion to identify physician (years in practice, practice set-
ting, percent of time spent performing clinical duties,
History of Present Illness: A 50 year old (African American or White) woman who is seeing a 
primary care physician for the first time.  She recently moved to the area and is seeking care 
from a new physician.  She has no complaints today. She has been taking her previously 
prescribed medications regularly.  
Past Medical History: The patient’s medical history includes hypertension (of 10 years 
duration) and obesity. (For diabetes scenario: The patient also had diabetes mellitus of 5 years 
duration.  She has no history of microvascular or macrovascular disease).
Social History: She is married, has 3 children, and works as an administrative assistant.  She 
is a non-smoker.  She is insured with an indemnity (fee for service) health insurance plan, 
which does not restrict her receipt of a referral to a specialist if needed.
Review of Systems: She wears eye glasses, sees an ophthalmologist annually, and has had 
normal ophthalmologic examinations.  Her remaining review of systems is negative, including 
no neurologic or vascular symptoms.
Medications: Diuretic and acetaminophen (For diabetes scenario:  the patient’s medication 
included angiotensin 2 receptor blocker and oral hypoglycemic agent)
Physical Examination: Blood pressure, 125/80 mm Hg, weight 154 pounds, height 5’2’’.  The 
remainder of her examination (including eye, cardiovascular, and neurologic exams performed 
by the primary care physician) is unremarkable.  
Laboratory Examination:
Laboratory Studies 4 months ago 1 week ago
Complete blood count Normal Normal
Electrolytes and liver function tests Normal Normal
BUN [mg/dL] 18 19
Serum creatinine [mg/dL]
2
White 1.8 2.0
African American 2.1 2.3
Proteinuria (gross dipstick) 1+ 1+
Hemoglobin A1c (for diabetes scenario) 6.3% 6.8%
Figure 1 Hypothetical case scenario. We provided primary care
physicians with one of four randomly assigned hypothetical
scenarios, which varied on patient race (African American or White)
and the presence or absence of diabetes. * Complete blood count
includes hemoglobin, hematocrit, platelet count, and white blood
cell count.
† For the “4 month ago values”, the estimated glomerular
filtration rate (eGFR) for the White and African American patient was
32 mL/min/1.73m
2 and for the “1 week ago” values the eGFR was
28 and 29 mL/min/1.73m
2, respectively (using the 4-variable
Modification of Diet in Renal Disease Study equation)[20].
Figure 2 Visual analog scales for serum creatinine and
estimated glomerular filtration rate (eGFR) levels. Physicians
were asked to mark on the visual analog scales the serum
creatinine level and the eGFR level at which they would
recommend a primary care physician refer a patient, like the patient
featured in the hypothetical scenario, for subspecialty care.
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ral) and hypothetical patient (diabetes presence and
race) characteristics independently associated with clini-
cally significant improvement in the timing of primary
care physicians’ referrals. We used Pearson’sc h i - s q u a r e
goodness of fit test to assess the model. We converted
adjusted odds ratios to absolute probabilities and their
corresponding 95% confidence intervals[27]. We per-
formed all statistical analyses with STATA version 9.2
(Statacorp, College Station, Texas). The funders had no
role in the conduct or conceptualization of this study.
Results
Study Participants
O ft h e1 7 8r e s p o n d i n gp r i m a r yc a r ep h y s i c i a n s ,1 5 4
answered questions regarding the serum creatinine and
eGFR level at which they would refer a patient, similar
to the patient featured in the hypothetical scenario, for
CKD subspecialty care. Responding and nonresponding
primary care physicians did not differ in years in prac-
tice (median (interquartile range): 12 (3-21) versus 12
(5-20), respectively; p = 0.64) or census region of prac-
tice (Northeast, 25% versus 20%, Midwest, 24% versus
25%; South, 29% versus 33%; and West 22% versus 22%,
respectively; p = 0.57).
A majority of primary care physicians practiced in non-
academic settings, practiced greater than 10 years, spent
greater than 80% of their time performing clinical duties,
and reported attending conferences or reading scientific
journals as an educational resource. Primary care physi-
cians most frequently reported turning to internal medi-
cine or non-nephrology specialty organizations for
clinical practice guidelines, while fewer reported turning
to United States Preventive Services Task Force or to
nephrology organizations. One third of primary care phy-
sicians reported they were aware of subspecialty referral
guidelines for patients with CKD, and a majority of these
physicians (84%) reported following these guidelines in
their own practices. Over half of primary care physicians
were presented with a hypothetical case scenario featur-
ing an African American patient or a patient with
diabetes. Primary care physicians were equally distributed
among census regions. (Table 1)
Effect of eGFR on the Timing of Primary Care Physicians’
Subspecialty Referrals
Primary care providers recommended patients for sub-
specialty care earlier when using eGFR compared to
when they used serum creatinine to estimate kidney
function. The median serum creatinine level (interquar-
tile range (IQR)) at which primary care physicians
recommended subspecialty referral was 2.0 (1.8-2.3)
mg/dL, corresponding to a median eGFR of 32 (26-36)
mL/min/1.73m
2) while the median eGFR level at which
primary care physicians recommended subspecialty refer-
ral was 55 (45-72) mL/min/1.73m
2 (p < 0.001). (Figure 3)
The median (IQR) absolute difference between eGFR and
creatinine-based eGFR referral levels was 23 (12-40) mL/
min/1.73m
2. The improvement in timing of referrals with
the use of eGFR was greater for physicians presented
with a White hypothetical patient compared to physi-
cians presented with an African American patient. There
were no differences in the timing of referrals based on
physicians’ use of eGFR according to patients’ presence
or absence of diabetes. (Table 2)
Table 1 Primary care physician and scenario
characteristics
Physician characteristics All N (%) N = 154
Physician Specialty
Internal medicine 84 (55)
Family physician 70 (45)
Years in practice:
≤ 10 years 76 (49)
>10 years 78 (51)
Practice type:
Academic 25 (16)
Other 128 (84)
Percent clinical time:
<80%, 23 (15)
≥ 80% 131 (85)
Census region:
Northeast 40 (26)
Midwest 33 (21)
South 45 (29)
West 36 (23)
Aware of referral guidelines
Yes 49 (32)
No 103 (68)
Educational resources:
Conferences 134 (88)
Scientific journals 144 (95)
Other 78 (53)
Guideline organizations:
Nephrology 46 (29)
Internal medicine 118 (77)
USPSTF 77 (50)
Specialty 101 (66)
Clinical scenario:
Patient race: African American 84 (55)
Diabetes 89 (58)
Note. Due to missing values, categorical frequencies may not equal column
total. For educational resources and guideline organizations, selections were
not mutually exclusive.
ZIP code used for census region.
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all (94%) primary care physicians’ recommended refer-
rals when eGFR was ≥ 30mL/min/1.73m
2 compared to
55% of primary care physicians’ making similar recom-
mendations when using serum creatinine. Over a third
of primary care physicians (40%) significantly improved
the timing of their referrals when basing their recom-
mendations on eGFR. In multivariable models, improved
timing of referral recommendations was more prevalent
among primary care physicians practicing in academic
(versus non-academic) practices and physicians pre-
sented with hypothetical scenarios featuring a White
(versus an African American) patient. (Table 3)
Discussion
In this national study, U.S. primary care physicians
referred patients for subspecialty care earlier when they
based their referral decisions on patients’ eGFR com-
pared to when they based their referral decisions on
serum creatinine. Over a third of primary care physicians
significantly improved the timing of their decisions with
the use of eGFR. Improved timing of referrals was greater
among primary care physicians practicing in academic
settings and presented with White hypothetical patients.
These findings provide insight regarding the potential
impact of clinical laboratories’ automatic reporting of
eGFR on clinical care and patient outcomes.
To our knowledge, this is the first U.S. study to
demonstrate the effect of primary care physicians’ use of
eGFR on the timing of their subspecialty referral
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Figure 3 Recommended serum creatinine and estimated
glomerular filtration rate (eGFR)-based referral levels by
primary care providers. Note. Lines and bars represent the range
and interquartile range of selected values, respectively.
Abbreviations. eGFR, estimated glomerular filtration rate.
Table 2 Recommended serum creatinine and estimated
glomerular filtration rate (eGFR)-based referral levels by
characteristics of the hypothetical patient
Median referral level mL/min/1.73m
2
Creatinine-
based eGFR*
p
value
eGFR p
value
Absolute
difference
p
value
Race <0.001 0.47 0.03
African
American
34 54 19
White 28 55 26
Diabetes 0.90 0.42 0.34
Yes 32 60 26
No 32 50 22
*The recommended median serum creatinine at referral for all versions of the
clinical scenario was 2 mg/dL.
Table 3 Percent of primary care physicians with clinically
significant improvement in the timing of their
subspecialty referral recommendations with the use of
estimated glomerular filtration rate (eGFR) by physician
and scenario characteristics
Physician characteristics % of primary care physicians with
clinically significant improvement in
their subspecialty referral
recommendations
*
Unadjusted p
value
Adjusted
†
(95% CI)
p
value
Years in practice:
>10 years 44 0.31 50 (32-68) 0.11
≤ 10 years 36 36 (Ref)
Practice type:
Academic 56 0.07 70 (45-87) 0.01
Other 37 37 (Ref)
Percent clinical time:
<80%, 26 0.15 23 (8-49) 0.13
≥ 80% 42 42 (Ref)
Census region:
Midwest 33 0.65 38 (18-64) 0.47
South 38 40 (20-64) 0.56
West 39 41 (20-66) 0.60
Northeast 48 48 (Ref)
Aware of referral
guidelines:
Yes 29 0.06 29 (15-48) 0.09
No 45 45 (Ref)
Clinical scenario:
Patient race:
White 57 <0.001 57 (39-73) <0.001
African American 25 25 (Ref)
Diabetes
Yes 43 0.36 42 (26-61) 0.44
No 35 35 (Ref)
Note. A total of 152 participants with complete data were included in the
model.
*Clinically significant improvement in subspecialty referral recommendations
was defined as present, if primary care physicians selected a serum creatinine-
based referral level corresponding to an estimated glomerular filtration rate
(eGFR) level of < 30 mL/min/1.73m
2, but recommended subspecialty referral
at level of ≥ 30 mL/min/1.73m
2 with the use of eGFR.
†Adjusted for all variables in the table.
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ing the association of eGFR reporting with CKD speci-
alty referral practices were limited by their inability to
account for various clinical and non-clinical policy and
resource trends which could have also impacted referral
practices[28-34]. Our study was designed to directly
assess the impact of the use of eGFR on physician deci-
sion making under the same patient, provider, and sys-
tem level influences. Our findings provide evidence that
encouraging use of eGFR by primary care providers to
assess kidney function and more widespread automatic
reporting of eGFR by clinical laboratories could signifi-
cantly improve the quality of care and clinical outcomes
for patients with CKD by directly affecting physicians’
clinical decisions. Earlier referrals to subspecialty care
for the roughly one million U.S. adults with advancing
CKD (defined as National Kidney Foundation Kidney
Disease Outcome Quality Initiative stages 3 and 4 CKD
with gross proteinuria) could impact several aspects of
clinical care for these patients, including allowing for
appropriate dosing of medications to accommodate
impaired renal function, earlier avoidance of nephrotox-
ins which could hasten CKD progression, achievement
of CKD directed blood pressure and lipid targets, treat-
ment of early metabolic complications of CKD, as well
as earlier preparation for renal replacement therapy, all
of which have been recommended and many of which
have been demonstrated to improve clinical outcomes
[1,3,7,35-43].
There was substantial variation in the levels of eGFR
at which U.S. primary care physicians recommended
referral (ranging from eGFR of 15 to 100 mL/min/
1.73m
2), suggesting refinement of clinical practice guide-
lines to clarify the indications for referral may be
needed. While very early referrals may be appropriate
for patients with gross proteinuria or rapidly declining
kidney function, very early referrals among some
patients with less risk of progression (e.g. elderly per-
sons with reduced but relatively stable kidney function)
may be inappropriate with regard to resource utilization
and availability of nephrologists[44,45]. Guidelines’ clari-
fication of clinical circumstances requiring more urgent
referrals, as well as dissemination of these recommenda-
tions, may provide primary care physicians with greater
confidence to care for the growing number of patients
with CKD.
Differences in serum creatinine based on patient race
and gender are well-established (with greater serum
creatinine levels among men and African Americans)
[46]. The extent to which our finding of physicians’
greater improvement in the timing of referrals among
Whites compared to African Americans reflects race-
based inequities in care is unclear. Since we presented
each physician with only one hypothetical patient
scenario (featuring a patient of either White or African
American race), we were unable to ascertain whether
individual physicians’ practice patterns would have
changed if they saw patients of different races. It is
highly possible later referrals of Whites based on serum
creatinine reflects primary care physicians’ lack of
knowledge regarding the severity of kidney dysfunction
associated with lower serum creatinine levels among
Whites. In light of previous research demonstrating
Blacks are more likely to receive later subspecialty refer-
rals compared to Whites[4], our findings of equal refer-
ral timing among African Americans and Whites when
primary care physicians used eGFR to estimate kidney
dysfunction provides some reassurance that the use of
eGFR may help narrow race-based differences in the
timing of subspecialty referrals. The extent to which
physicians’ enhanced use of eGFR could narrow racial
disparities in the long-term clinical outcomes of patients
with CKD merits further study.
There are limitations of this study. First, physicians’
recommendations for referral based on a hypothetical
case scenario may not reflect their real practice patterns.
Further, serum creatinines provided in the scenario
might have caused an anchoring effect for the respon-
dents when providing recommendations for referral
based on serum creatinine. However, the use of a
hypothetical case allowed us to assess physicians’ deci-
sion-making regarding referral under similarly realistic
conditions, and the inclusion of serum creatinine in the
scenario would not have impacted within-individual-
physician differences in their referrals when using serum
creatinine versus eGFR. Second, we did not assess the
rationale for the timing of physicians’ referrals, which
may have been based on factors other than the eGFR (i.
e. presence of proteinuria or diabetes). Third, the study
sample size was small, and primary care physicians’
response rate was limited, possibly limiting our ability to
detect all significant associations and the generalizability
of our findings. Nonetheless, participating physicians
practiced in several regions of the U.S. and in a variety
of practice settings enhancing our ability to identify phy-
sician characteristics associated with improvement in the
timing of referrals. Finally, the cross-sectional design of
our study limits our ability to assess the potential long-
term effects of physicians’ eGFR referral decisions on
patients’ clinical outcomes. However, extensive research
documenting poor clinical outcomes for patients experi-
encing late referrals for subspecialty care supports the
potential significance of our findings[3,4].
Conclusions
In conclusion, we found U.S. primary care physicians
recommended subspecialty referrals earlier when asses-
s i n gt h es e v e r i t yo fk i d n e yd y s f u n c t i o nu s i n ge G F R
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Physicians practicing in academic primary care settings
and reviewing a hypothetical scenario featuring a White
patient were more likely to improve the timing of their
referral recommendations when using eGFR. Increased
use of eGFR by primary care providers, in addition to
more wide spread automated reporting of eGFR by U.S.
clinical laboratories could improve the timing of subspe-
cialty care and clinical outcomes for patients with CKD.
Race-based differences in improved timing of referral
with the use of eGFR warrant further study.
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